Bristol Myers Squibb’s checkpoint inhibitor combination product Opdualag (nivolumab/relatlimab) sustained a Phase III failure in a study that might have expanded the drug’s label into the adjuvant setting in late-stage melanoma, but the company said it remains hopeful of getting the drug approved in other cancer types, such as non-small cell lung cancer.
Key Takeaways
- Bristol Myers Squibb no longer plans to test Opdualag in adjuvant melanoma after a Phase III study failed to demonstrate recurrence-free survival.
After the markets closed on 13 February, BMS reported that Opdualag did not meet the primary endpoint of recurrence-free survival...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?